LE GINECO À L’ESMO 2020 !

GYNECOLOGICAL ORAL SESSION

IMagyn050  21 septembre à 16h20  LBA31

GYNECOLOGICAL MINI ORAL SESSION

TAPAZ  Abstract # 808MO
PAOLA-1 – PFS2  Abstract# LBA33
PAOLA-1 – Response rate  Abstract # 812MO
PRIMA – PRO  Abstract # 810MO
SOLO1 – Follow-up (5 years)  Abstract# 811MO
SOLO2 – Subsequent therapies  Abstract # 813MO
CA-125 KELIM  Abstract # 815MO
DESKTOPIII – Time to first subsequent therapy  Abstract # 816MO

SARS- Cov-2 and cancer MINI ORAL SESSION

THE GCO -002 CACOVID -19 cohort  Abstract # 1673MO

GYNECOLOGICAL e-POSTER SESSION

RETLORA  Abstract # 823P
REGOVAR  Abstract # 829P

BREAST e-POSTER SESSION

PADA-1  Abstract # 304P
PAOLA-1  Antonio Gonzales Martin - Abstract #LBA33
Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the Phase III PAOLA-1/ENGOT-ov25 trial

SOLO1  Susana Banerjee – Abstract #811MO
Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

SOLO2  J-Sébastien Frenel – Abstract #813MO
Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

CA125 KELIM  Benoît You – Abstract #815MO
The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients

DESKTOPIII  Fabrice Lécru – Abstract #816MO
AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)